YU91403A - Antitela specifična za cd44v6 - Google Patents

Antitela specifična za cd44v6

Info

Publication number
YU91403A
YU91403A YU91403A YUP91403A YU91403A YU 91403 A YU91403 A YU 91403A YU 91403 A YU91403 A YU 91403A YU P91403 A YUP91403 A YU P91403A YU 91403 A YU91403 A YU 91403A
Authority
YU
Yugoslavia
Prior art keywords
antibody
antibody proteins
cd44v6
antibodies specific
antibodies
Prior art date
Application number
YU91403A
Other languages
English (en)
Inventor
Gunther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Karl-Heinz Heider
John J. Miglietta
Augustinus A.M.S. Van Dongen
Original Assignee
Boehringer Ingelheim International Gmbh.
Boehringer Ingelheim Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh., Boehringer Ingelheim Pharmaceuticals Inc. filed Critical Boehringer Ingelheim International Gmbh.
Publication of YU91403A publication Critical patent/YU91403A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Predmetni pronalazak pripada oblasti onkologije. Pronalazak se odnosi na antitela sa specifikovanom sekvencom koja su specifična za epitop koji je kodiran sa varijantom egzona v6 gena CD44 i na derivate pomenutog antitela. Pronalazak se takodje odnosi i na molekule nukleinskih kiselina koji kodiraju pomenute proteine antitela. Pronalazak pored toga obuhvata i postupke za dobijanje pomenutih proteina antitela. Osim toga, pronalaskom su takodje realizovane i farmaceutske kompozicije koje sadrže pomenute proteine antitela. Pored toga, pronalazak se dalje odnosi i na njihovu primenu za dobijanje leka za lečenje raka.[The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
YU91403A 2001-05-18 2002-05-17 Antitela specifična za cd44v6 YU91403A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US32514701P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
YU91403A true YU91403A (sh) 2006-05-25

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
YU91403A YU91403A (sh) 2001-05-18 2002-05-17 Antitela specifična za cd44v6

Country Status (18)

Country Link
EP (1) EP1397387A1 (sh)
JP (1) JP2005504517A (sh)
CN (1) CN1541226A (sh)
AR (1) AR036154A1 (sh)
BR (1) BR0210905A (sh)
CA (1) CA2443437A1 (sh)
CZ (1) CZ20033476A3 (sh)
EA (1) EA200301169A1 (sh)
EC (1) ECSP034838A (sh)
EE (1) EE200300569A (sh)
HU (1) HUP0400030A3 (sh)
MX (1) MXPA03010523A (sh)
PE (1) PE20021098A1 (sh)
PL (1) PL365735A1 (sh)
SK (1) SK15592003A3 (sh)
WO (1) WO2002094879A1 (sh)
YU (1) YU91403A (sh)
ZA (1) ZA200307365B (sh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
WO2006099141A2 (en) 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
EP1879922A2 (en) 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
CA2690119A1 (en) * 2007-06-13 2008-12-24 Ares Trading S.A. Use of taci-ig fusion protein such as atacicep for the manufacture of a medicament for treating lupus erythematosus
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
MA34010B1 (fr) 2010-02-04 2013-02-01 Hoffmann La Roche Anticorps monoclonal anti-cd44 destiné à être utilisé pour traiter le carcinome à cellules squameuses de la tête et du cou
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
WO2022187591A1 (en) * 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
CA2149635A1 (en) * 1992-11-20 1994-06-09 David Tarin Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Also Published As

Publication number Publication date
HUP0400030A3 (en) 2006-02-28
JP2005504517A (ja) 2005-02-17
EE200300569A (et) 2004-04-15
HUP0400030A2 (hu) 2004-04-28
WO2002094879A1 (en) 2002-11-28
ECSP034838A (es) 2003-12-24
EP1397387A1 (en) 2004-03-17
CN1541226A (zh) 2004-10-27
PL365735A1 (en) 2005-01-10
EA200301169A1 (ru) 2004-06-24
SK15592003A3 (sk) 2004-06-08
BR0210905A (pt) 2004-06-08
AR036154A1 (es) 2004-08-18
PE20021098A1 (es) 2003-02-11
CA2443437A1 (en) 2002-11-28
ZA200307365B (en) 2004-05-10
MXPA03010523A (es) 2004-07-01
CZ20033476A3 (cs) 2004-05-12

Similar Documents

Publication Publication Date Title
YU91403A (sh) Antitela specifična za cd44v6
SG170080A1 (en) Human monoclonal antibodies to o8e
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
MX2020012327A (es) Anticuerpo antagonista de cd73.
SG10201408073XA (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
ATE516047T1 (de) Ovr110-antikörperzusammensetzungen und anwendungsverfahren
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ATE462726T1 (de) Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
EA200800094A1 (ru) Антитела cd19 и их использование
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
WO2005097185A3 (en) Irta-5 antibodies and their uses
ATE420160T1 (de) Modifizierte rekombinante vacciniaviren, verwendungen davon
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2007038637A3 (en) Human monoclonal antibodies to cd70
WO2006076691A8 (en) Irta-2 antibodies and their uses
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
HK1094876A1 (en) Method of producing recombinant antibodies against tumours
ATE514718T1 (de) Peptabody für krebsbehandlung
AU2002318934A1 (en) Sak: modulation of cellular proliferation for treatment of cancer
UY27298A1 (es) Anticuerpos específicos de cd44v6
PT914417E (pt) Dnase ii humana
ATE463566T1 (de) Tumor- und seneszenzsmarker